2015年3月22日讯/生物谷BIOON/--据估计，2023年全球1型糖尿病市场将达到136亿美元，而2013年这个数字仅仅是66亿美元。
GlobalData分析，美国仍将是1型糖尿病药物最大的市场，美国的胰岛素价格比其它主要国家高出5至6倍。
2023年的全球1型糖尿病药物市场达到136亿美元，而2013年的市场总额仅仅是66亿美元，以7.6%的年复合增长率增长。
1型糖尿病药物的主要市场是美国、法国、德国、意大利、西班牙、英国、日本以及加拿大，推动增长率的因素除了越来越高的发病率之外，药物价格上涨导致的成本增加也是主要的因素。
2013年，美国占据了全球74%的1型糖尿病药物市场份额，收益大约为48亿美元。到2023年，美国所占全球市场份额将会达到78%，市场份额以8.2%的年复合增长率增长，达到105亿美元。
GlobalData的心血管疾病与代谢疾病治疗部门的主管Valentina Gburcik表示，美国未来仍能够保持最高的市场份额，主要原因是美国的胰岛素价格最高，是其它几个主要国家的5到6倍。比方说赛诺菲的胰岛素——Lantus在美国的售价是1621美元，而在几个欧洲国家仅仅是320美元。此外，尽管2023年将会有7个胰岛素产品的专利到期，但是新型的长效胰岛素、高效胰岛素类似物以及辅助治疗法都会抵消价格下降带来的市场总额缩小。
GlobalData的报告还表示，至少在可预见的下个十年中，人胰岛素以及胰岛素类似物还将是1型糖尿病治疗的一线药物，因为尚未出现能够完全使胰岛b细胞再生的方法。
然而，治疗2型糖尿病的GLP-1 RAs和SGLT-2抑制剂有可能于2017年获批治疗1型糖尿病。这将对1型糖尿病的治疗领域造成重大的冲击，这两种药物将会分别占据9%和11%的市场份额。不过这两种药物还是无法完全媲美胰岛素，估计将会以辅助治疗的形式开处方，主要用于肥胖的1型糖尿病患者和1型、2型混合的糖尿病患者。
原文 Type 1 diabetes market to double to $13.6bn
The global treatment market for type 1 diabetes will expand from $6.6bn in 2013 to an estimated $13.6bn by 2023.
This is according to analysts from GlobalData， who found that the US would remain biggest T1D treatment market with average insulin price five to six times higher than other major countries.
The global treatment market for type 1 diabetes will expand from $6.6bn in 2013 to an estimated $13.6bn by 2023， representing a compound annual growth rate (CAGR) of 7.6%.
The company's latest report states that across the eight major markets of the US， France， Germany， Italy， Spain， UK， Japan， and Canada， growth will be driven primarily by increasing T1D incidence and the substantially higher annual cost of therapy (ACoT) in the US.
The US had a 74% share of the global T1D treatment space in 2013 with revenues of $4.8bn. This share will rise to 78% by 2023， with the market expanding at a CAGR of 8.2% to reach $10.5bn.
Valentina Gburcik， GlobalData's therapy director of cardiovascular and metabolic disorders， says： “The US will remain the leading market largely thanks to its average insulin price， which is about five to six times greater than in the other major markets. For example， the ACoT of Sanofi's Lantus is $1，621 in the US， compared to around $320 in EU countries.
“Furthermore， the uptake of novel ultra-long-acting insulin analogs， novel ultra-rapid formulations of insulin analogs， and adjunct therapies for T1D in the US market will help to offset the dip in sales caused by the patent expiries of seven insulin products by 2023.”
GlobalData's report also states that human insulins and insulin analogs will remain front-line therapies for T1D， as none of the treatments on the horizon for the next 10 years will have the capacity to enable full regeneration of pancreatic beta cells.
However， Gburcik notes that therapies currently used for type 2 diabetes， namely GLP-1 RAs and SGLT-2 inhibitors， are expected to be approved for T1D from around 2017.
They will have a considerable impact on the global T1D market by 2023， constituting 9% and 11% of the arena， respectively.
“These therapies will not compete with the insulins， as they will be prescribed as adjunct， add-on treatments. They will be used particularly in obese T1D patients and those with a mixed T1D/T2D phenotype，” the director concludes